ATE526408T1 - Modulatoren von dem körpergewicht, entsprechende nukleinsaüre und proteine, und diagnostische und therapeutische anwendungen davon - Google Patents

Modulatoren von dem körpergewicht, entsprechende nukleinsaüre und proteine, und diagnostische und therapeutische anwendungen davon

Info

Publication number
ATE526408T1
ATE526408T1 AT95929591T AT95929591T ATE526408T1 AT E526408 T1 ATE526408 T1 AT E526408T1 AT 95929591 T AT95929591 T AT 95929591T AT 95929591 T AT95929591 T AT 95929591T AT E526408 T1 ATE526408 T1 AT E526408T1
Authority
AT
Austria
Prior art keywords
body weight
modulators
present
diagnostic
nucleic acids
Prior art date
Application number
AT95929591T
Other languages
English (en)
Inventor
Jeffrey FRIEDMAN
Yiying Zhang
Ricardo Proenca
Margherita Maffei
Jeffrey Halaas
Ketan Gajiwala
Stephen BURLEY
Original Assignee
Univ Rockefeller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23124262&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE526408(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/438,431 external-priority patent/US6429290B1/en
Priority claimed from US08/483,211 external-priority patent/US6309853B1/en
Application filed by Univ Rockefeller filed Critical Univ Rockefeller
Application granted granted Critical
Publication of ATE526408T1 publication Critical patent/ATE526408T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/12—Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT95929591T 1994-08-17 1995-08-17 Modulatoren von dem körpergewicht, entsprechende nukleinsaüre und proteine, und diagnostische und therapeutische anwendungen davon ATE526408T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/292,345 US6001968A (en) 1994-08-17 1994-08-17 OB polypeptides, modified forms and compositions
US08/347,563 US5935810A (en) 1994-08-17 1994-11-30 Mammalian ob polypeptides capable of modulating body weight, corresponding nucleic acids, and diagnostic and therapeutic uses thereof
US08/438,431 US6429290B1 (en) 1994-08-17 1995-05-10 OB polypeptides, modified forms and derivatives
US08/483,211 US6309853B1 (en) 1994-08-17 1995-06-07 Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
PCT/US1995/010479 WO1996005309A2 (en) 1994-08-17 1995-08-17 Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof

Publications (1)

Publication Number Publication Date
ATE526408T1 true ATE526408T1 (de) 2011-10-15

Family

ID=23124262

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95929591T ATE526408T1 (de) 1994-08-17 1995-08-17 Modulatoren von dem körpergewicht, entsprechende nukleinsaüre und proteine, und diagnostische und therapeutische anwendungen davon

Country Status (11)

Country Link
US (8) US6001968A (de)
EP (1) EP2402444A1 (de)
CN (1) CN102002102A (de)
AT (1) ATE526408T1 (de)
CO (1) CO4410343A1 (de)
DK (1) DK0777732T3 (de)
IL (2) IL162093A (de)
LT (1) LT4265B (de)
PT (1) PT777732E (de)
SI (1) SI0777732T1 (de)
ZA (1) ZA956868B (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001968A (en) * 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
EP0804548B1 (de) 1994-10-07 2005-07-13 The Board Of Trustees Of The Leland Stanford Junior University Ptc gene und ihre verwendung
US6946257B1 (en) 1994-10-07 2005-09-20 Regents Of The University Of California Patched genes and uses related thereto
US6429354B1 (en) 1994-10-07 2002-08-06 The Board Of Trustees Of The Leland Stanford Junior University Patched genes and uses related thereto
US6936439B2 (en) * 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
US20030040467A1 (en) * 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
US6977240B1 (en) * 1995-11-27 2005-12-20 Millenium Pharmaceuticals, Inc. Methods of using the OB receptor antibodies to treat bodyweight disorders
US6620413B1 (en) * 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
US20050019325A1 (en) * 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
US6541604B1 (en) 1996-01-08 2003-04-01 Genentech, Inc. Leptin receptor having a WSX motif
US7074397B1 (en) 1996-01-08 2006-07-11 Genentech, Inc. Method for enhancing proliferation or differentiation of a cell using ob protein
US7067472B1 (en) 1996-06-04 2006-06-27 The Scripps Research Institute Diagnostic and therapeutic methods related to regulating energy mobilization with OB protein and OB antibodies
US6277592B1 (en) * 1996-07-31 2001-08-21 Purina Mills, Inc. Porcine leptin protein, nucleic acid sequences coding therefor and uses thereof
US6297027B1 (en) 1996-07-31 2001-10-02 Purina Mills, Inc. Bovine leptin protein, nucleic acid sequences coding therefor and uses thereof
US6399745B1 (en) * 1996-09-20 2002-06-04 Aventis Pharma Deutschland Gmbh Use of leptin antagonists for treating insulin resistance in type II diabetes
US6777388B1 (en) * 1998-08-21 2004-08-17 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
US6420339B1 (en) * 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
US20030215423A1 (en) * 1999-04-01 2003-11-20 Merck & Co., Inc. Gene therapy for obesity
AU767068B2 (en) * 1999-06-11 2003-10-30 Baylor College Of Medicine Methods and compositions for control of bone formation via modulation of leptin activity
CA2388417A1 (en) * 1999-09-22 2001-03-29 Genset Methods of screening for compounds that modulate the lsr-leptin interaction and their use in the prevention and treatment of obesity-related diseases
WO2002061036A2 (en) * 2000-11-30 2002-08-08 The Research Foundation Of State University Of New York Method of complexing a protein by the use of a dispersed system and proteins thereof
US7625584B2 (en) * 2000-11-30 2009-12-01 The Research Foundation Of State University Of New York Method of complexing a protein by the use of a dispersed system and proteins thereof
US8110218B2 (en) * 2000-11-30 2012-02-07 The Research Foundation Of State University Of New York Compositions and methods for less immunogenic protein-lipid complexes
AU2002239607A1 (en) * 2000-11-30 2002-06-11 Baxter Healthcare Corporation Ahf associated dispersion system and method for preparation
US6869766B2 (en) * 2000-12-22 2005-03-22 The Regents Of The University Of California Gene associated with regulation of adiposity and insulin response
US7054758B2 (en) * 2001-01-30 2006-05-30 Sciona Limited Computer-assisted means for assessing lifestyle risk factors
US7329725B1 (en) * 2003-10-29 2008-02-12 Nastech Pharmaceutical Company Inc. Phage displayed Trp cage ligands
WO2006014798A2 (en) * 2004-07-27 2006-02-09 Mount Sinai School Of Medicine Methods and compositions for using sax2
ES2258923B1 (es) * 2005-02-23 2007-11-01 Universitat De Les Illes Balears Uso de la leptina para la prevencion del exceso de peso corporal y composicion que contiene leptina.
US8227408B2 (en) * 2005-09-07 2012-07-24 Neurotez, Inc. Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology
KR100763251B1 (ko) * 2006-02-01 2007-10-04 삼성전자주식회사 웨이퍼 이송 장치
CA2715080C (en) 2007-09-28 2021-09-28 Intrexon Corporation Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof
AU2009248914A1 (en) * 2008-05-21 2009-11-26 Neurotez, Inc. Methods for Treating Neurodegenerative Disorders Related to Neurofibrillary Tangles
US8501686B2 (en) * 2008-06-05 2013-08-06 University Of Michigan Method of treating fatty liver diseases and conditions in non-lipodystrophic subjects
WO2010054017A1 (en) * 2008-11-04 2010-05-14 Nikolaos Tezapsidis Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amlyoid beta
EP3241558B1 (de) 2010-09-28 2021-03-03 Aegerion Pharmaceuticals, Inc. Hochlösliche leptine
BR112015006848A2 (pt) 2012-09-27 2018-05-22 Childrens Medical Ct Corp formulação farmacêutica, método de indução de perda de peso, método de redução de gordura corporal, método de redução de ingesta de comida, método para melhorar homeostase de glicose e método para prevenir um aumento do índice de massa corporal de um paciente normal, pré-obeso, obeso ou obeso mórbido.
CN102925468A (zh) * 2012-09-28 2013-02-13 长春长理康源生物技术有限公司 小鼠肝脏羧酸酯酶基因克隆表达
WO2015081093A1 (en) 2013-11-26 2015-06-04 The Chilren's Medical Center Corporation Compounds for the treatment of obesity and methods of use thereof
WO2015153933A1 (en) 2014-04-03 2015-10-08 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
CN105132566A (zh) * 2015-09-21 2015-12-09 上海中优生物高科技有限责任公司 毒素堆积型肥胖基因个体化干预饮品的制备方法及其系统
EP3509624B1 (de) 2016-09-12 2023-08-09 Amryt Pharmaceuticals Inc. Verfahren zum nachweis von anti-leptin-neutralisierenden antikörpern
EP3774841A1 (de) 2018-08-27 2021-02-17 Regeneron Pharmaceuticals, Inc. Verwendung von ramanspektroskopie in einer nachgeschalteten reinigung
CN111200641B (zh) * 2019-12-25 2022-06-21 深圳供电局有限公司 数据跨链共享方法、系统，计算机设备和存储介质
CN115368441B (zh) * 2022-09-21 2025-06-13 湖北省农业科学院农产品加工与核农技术研究所 一种高效降血压水产品活性肽的制备方法
WO2024126571A1 (en) * 2022-12-14 2024-06-20 Universite de Bordeaux Artificial bifunctional enzyme comprising a myeloperoxidase activity and a glucose oxidase activity and applications thereof

Family Cites Families (162)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US31006A (en) * 1861-01-01 Feeding mechanism for spoke-machines
US3654090A (en) * 1968-09-24 1972-04-04 Organon Method for the determination of antigens and antibodies
USRE31006E (en) 1968-09-24 1982-08-03 Akzona Incorporated Process for the demonstration and determination of reaction components having specific binding affinity for each other
US3650090A (en) * 1970-06-19 1972-03-21 Phillips Petroleum Co Analysis of gaseous mixtures
NL154598B (nl) * 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4016043A (en) * 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4491632A (en) * 1979-10-22 1985-01-01 The Massachusetts General Hospital Process for producing antibodies to hepatitis virus and cell lines therefor
US4444887A (en) * 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4342566A (en) * 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
DE3167442D1 (en) * 1980-07-07 1985-01-10 Nat Res Dev Improvements in or relating to cell lines
US4341761A (en) * 1980-07-25 1982-07-27 E. I. Du Pont De Nemours And Company Antibodies to immunogenic peptides and their use to purify human fibroblast interferon
US4466917A (en) * 1981-02-12 1984-08-21 New York University Malaria vaccine
US4493890A (en) * 1981-03-23 1985-01-15 Miles Laboratories, Inc. Activated apoglucose oxidase and its use in specific binding assays
US4451570A (en) * 1981-03-26 1984-05-29 The Regents Of The University Of California Immunoglobulin-secreting human hybridomas from a cultured human lymphoblastoid cell line
US4399121A (en) * 1981-11-04 1983-08-16 Miles Laboratories, Inc. Iodothyronine immunogens and antibodies
US4427783A (en) * 1981-12-14 1984-01-24 Hoffmann-La Roche Inc. Immunoassay of thymosin α1
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4650764A (en) * 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US4631211A (en) * 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
EP0545913B1 (de) * 1986-08-18 1999-02-24 Emisphere Technologies, Inc. Abgabesysteme für Arzneimittel
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5071773A (en) * 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
US4980289A (en) * 1987-04-27 1990-12-25 Wisconsin Alumni Research Foundation Promoter deficient retroviral vector
US4981784A (en) * 1987-12-02 1991-01-01 The Salk Institute For Biological Studies Retinoic acid receptor method
US5010175A (en) * 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
JP2796388B2 (ja) 1988-05-13 1998-09-10 アムジエン・インコーポレーテツド Ｇ−ｃｓｆの精製方法
US5102789A (en) * 1989-03-15 1992-04-07 The Salk Institute Biotechnology/Industrial Associates, Inc. Production of epideramal growth factor in pichia pastoris yeast cells
IL91765A0 (en) * 1988-09-26 1990-06-10 Salk Inst Biotech Ind Mixed feed recombinant yeast fermentation
JP2989002B2 (ja) * 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
US5124263A (en) * 1989-01-12 1992-06-23 Wisconsin Alumni Research Foundation Recombination resistant retroviral helper cell and products produced thereby
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5098833A (en) 1989-02-23 1992-03-24 Genentech, Inc. DNA sequence encoding a functional domain of a lymphocyte homing receptor
US5354844A (en) * 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
CH679945A5 (de) 1989-04-04 1992-05-15 Oetiker Hans Maschinen
WO1990014092A1 (en) * 1989-05-18 1990-11-29 Cell Genesys, Inc. Single-strand site-directed modification of mammalian genes in vivo
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5073627A (en) 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
WO1991006666A1 (en) * 1989-11-06 1991-05-16 Cell Genesys, Inc. Production of proteins using homologous recombination
EP0779362B2 (de) * 1989-12-22 2012-06-13 Laboratoires Serono SA DNS-Konstrukten zur Aktivierung und Veränderung der Expression von endogenen Genen
FR2658841B1 (fr) 1990-02-26 1993-06-11 Aerospatiale Procede et dispositif pour la realisation d'elements d'armature composes de fibres resistantes.
US5139749A (en) * 1990-06-22 1992-08-18 Tas, Inc. Fluidized calcining process
JPH04257973A (ja) * 1991-02-13 1992-09-14 Hitachi Ltd 設計支援装置及び設計支援方法
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
JP3507486B2 (ja) * 1991-03-15 2004-03-15 アムジエン・インコーポレーテツド 顆粒球コロニー刺激因子の肺内投与
US5268295A (en) 1991-05-31 1993-12-07 W. Alton Jones Cell Science Center, Inc. Mammalian adipocyte protein p154, nucleic acids coding therefor and uses thereof
ZA924674B (en) 1991-07-02 1993-04-28 Imclone Systems Inc Cysteine depleted il-6 mutein
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
IL105406A (en) * 1992-04-17 2000-01-31 Sankyo Co Derivatives of adipogenesis inhibitory factor processes for the preparation thereof and pharmaceutical compositions containing the same
ES2252732T3 (es) 1992-05-26 2006-05-16 Immunex Corporation Nueva citoquina que une cd30.
JPH08500483A (ja) * 1992-06-19 1996-01-23 ジョスリン ダイアビーティーズ センター インコーポレイテッド 糖尿遺伝子ｒａｄ：２型糖尿病特異性遺伝子
ES2279508T3 (es) 1992-11-13 2007-08-16 Immunex Corporation Ligando elk, una citoquina.
TW334433B (en) 1992-12-09 1998-06-21 Takeda Pharm Industry Co Ltd Crystalline salt of (S)-(+)-5-amino-2,4,6,7-tetramethyl-2-(4-phenylpiperidinomethyl)-2,3-dihydrobenzo(b)furan dihydrochloride their production and use
EP0601417A3 (de) * 1992-12-11 1998-07-01 Hoechst Aktiengesellschaft Physiologisch verträglicher und physiologisch abbaubarer, Kohlenhydratrezeptorblocker auf Polymerbasis, ein Verfahren zu seiner Herstellung und seine Verwendung
US5641672A (en) 1993-06-09 1997-06-24 The Trustees Of Columbia University In The City Of New York Cloning and uses of the genetic locus bcl-6
JPH09501055A (ja) * 1993-07-30 1997-02-04 ユニバーシティ オブ メディシン アンド デンティストリー オブ ニュージャージー 初代リンパ球への効率的遺伝子転移
US5575705A (en) 1993-08-12 1996-11-19 Church & Dwight Co., Inc. Slurry blasting process
US5874075A (en) 1993-10-06 1999-02-23 Amgen Inc. Stable protein: phospholipid compositions and methods
DE69521880T2 (de) 1994-02-08 2002-01-03 Amgen Inc., Thousand Oaks Orales verabreichungssystem von chemischmodifizierten proteinen g-csf
DE4411065A1 (de) 1994-03-30 1995-10-05 Bayer Ag Kationische Thiadiazol-Farbstoffe
CZ283219B6 (cs) 1994-07-22 1998-02-18 F. Hoffmann-La Roche Ag Použití chimerního proteinu vázajícího TNF pro výrobu farmaceutického prostředku k ošetřování autoimunních nemocí
NZ292124A (en) 1994-07-29 1998-10-28 Smithkline Beecham Plc Il-4 antagonist comprising a fusion of a mutant il-4-antibody fragment
US5574018A (en) 1994-07-29 1996-11-12 Amgen Inc. Conjugates of vitamin B12 and proteins
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6471956B1 (en) 1994-08-17 2002-10-29 The Rockefeller University Ob polypeptides, modified forms and compositions thereto
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
US6001968A (en) * 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US5861485A (en) * 1994-08-23 1999-01-19 Millennium Pharmaceuticals, Inc. Polypeptides involved in body weight disorders, including obesity
US5643748A (en) * 1994-09-14 1997-07-01 Progenitor, Inc. HU-B1.219, a novel human hematopoietin receptor
US5912123A (en) * 1994-09-14 1999-06-15 Progenitor, Inc. Detection of the leptin receptor in reproductive organs and methods for regulating reproductive biology
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
EP0793504B1 (de) 1994-12-12 2005-06-08 Beth Israel Deaconess Medical Center, Inc. Chimäre zytokine und ihre verwendung
US5827734A (en) 1995-01-20 1998-10-27 University Of Washington Materials and methods for determining ob protein in a biological sample
US5858967A (en) * 1995-01-20 1999-01-12 University Of Washington Appetite supression factor and related methods
US5569744A (en) * 1995-01-31 1996-10-29 Eli Lilly And Company Anti-obesity proteins
US5567803A (en) * 1995-01-31 1996-10-22 Eli Lilly And Company Anti-obesity proteins
US5559208A (en) * 1995-01-31 1996-09-24 Eli Lilly And Company Anti-obesity proteins
US5574133A (en) * 1995-01-31 1996-11-12 Eli Lilly And Company Anti-obesity proteins
AU4766596A (en) * 1995-01-31 1996-08-21 Eli Lilly And Company Ob gene product antibodies
US5691309A (en) * 1995-01-31 1997-11-25 Eli Lilly And Company Anti-obesity proteins
US5567678A (en) * 1995-01-31 1996-10-22 Eli Lilly And Company Anti-obesity proteins
US5563245A (en) * 1995-01-31 1996-10-08 Eli Lilly And Company Anti-obesity proteins
US5552523A (en) * 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5569743A (en) * 1995-01-31 1996-10-29 Eli Lilly And Company Anti-obesity proteins
US5563244A (en) * 1995-01-31 1996-10-08 Eli Lilly And Company Anti-obesity proteins
WO1996023514A1 (en) * 1995-01-31 1996-08-08 Eli Lilly And Company Anti-obesity proteins
US5521283A (en) * 1995-01-31 1996-05-28 Eli Lilly And Company Anti-obesity proteins
US5552522A (en) * 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5532336A (en) * 1995-01-31 1996-07-02 Eli Lilly And Company Anti-obesity proteins
US5580954A (en) * 1995-01-31 1996-12-03 Eli Lilly And Company Anti-obesity proteins
US5552524A (en) * 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5605886A (en) * 1995-01-31 1997-02-25 Eli Lilly And Company Anti-obesity proteins
US5594104A (en) * 1995-01-31 1997-01-14 Eli Lilly And Company Anti-obesity proteins
WO1996023515A1 (en) * 1995-01-31 1996-08-08 Eli Lilly And Company Anti-obesity proteins
US5525705A (en) * 1995-01-31 1996-06-11 Eli Lilly And Company Anti-obesity proteins
US5563243A (en) * 1995-01-31 1996-10-08 Eli Lilly And Company Anti-obesity proteins
US5554727A (en) * 1995-01-31 1996-09-10 Eli Lilly And Company Anti-obesity proteins
WO1996024670A1 (en) * 1995-02-06 1996-08-15 Eli Lilly And Company Human obesity gene
US5594101A (en) * 1995-03-03 1997-01-14 Eli Lilly And Company Anti-obesity proteins
US5719266A (en) 1995-03-17 1998-02-17 Eli Lilly And Company Anti-obesity proteins
US6068976A (en) * 1995-03-20 2000-05-30 Ligand Pharmaceuticals Incorporated Modulators of ob gene and screening methods therefor
JPH08333394A (ja) * 1995-04-03 1996-12-17 Takeda Chem Ind Ltd ラット肥満遺伝子、その遺伝子産物およびその製造法
EP0736599A3 (de) * 1995-04-03 1996-12-11 Takeda Chemical Industries Ltd Das Obesitätsgen der Ratte, sein Genprodukt und dessen Herstellung
AU5539596A (en) * 1995-04-06 1996-10-23 Amylin Pharmaceuticals, Inc. Anti-obesity agents
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5614379A (en) * 1995-04-26 1997-03-25 Eli Lilly And Company Process for preparing anti-obesity protein
GB9509164D0 (en) * 1995-05-05 1995-06-28 Smithkline Beecham Plc Novel compounds
ES2093593T1 (es) 1995-05-05 1997-01-01 Hoffmann La Roche Proteinas obesas (ob) recombinantes.
WO1996035787A1 (en) * 1995-05-08 1996-11-14 Chiron Corporation Nucleic acids for treating obesity
AU5795496A (en) * 1995-05-19 1996-11-29 Eli Lilly And Company Obesity gene product
US5766851A (en) * 1995-05-19 1998-06-16 The Johns Hopkins University School Of Medicine Susceptibility gene for obesity and type II diabetes mellitus
EP0744408A3 (de) * 1995-05-26 1997-01-02 Eli Lilly And Company Das ob Protein der Rhesusaffen und seine DNA
CN1192248A (zh) * 1995-05-30 1998-09-02 史密丝克莱恩比彻姆有限公司 检测调节肥胖症蛋白作用的化合物的方法
EP0831835B1 (de) * 1995-06-01 2002-10-30 Eli Lilly And Company Behandlung der anorexie
US5849708A (en) 1995-06-06 1998-12-15 Joslin Diabetes Center, Inc. Promotion of eating behavior
CA2223433C (en) * 1995-06-07 2003-11-18 Amgen Inc. Ob protein compositions and methods
IT1278696B1 (it) * 1995-06-07 1997-11-27 Edi Bondioli Componente tubolare per alberi di trasmissione telescopici
GB9511935D0 (en) * 1995-06-13 1995-08-09 Smithkline Beecham Plc Novel compound
JPH11508248A (ja) * 1995-06-22 1999-07-21 ノバルティス アクチェンゲゼルシャフト 農薬用トリス・オキシイミノ複素環式化合物
EP0759441A3 (de) * 1995-06-30 1999-06-30 Eli Lilly And Company Verfahren zur Behandlung von mit Neuropeptid Y assozierten Zuständen
CA2225454A1 (en) * 1995-06-30 1997-01-23 Thomas Wesley Stephens Methods for treating diabetes
DE69631605T2 (de) * 1995-08-17 2005-01-05 Amgen Inc., Thousand Oaks Verfahren zur verringerung und zur erhaltung von verringerten blutspiegeln von lipiden mittels zubereitungen von ob-proteinen
JPH11512296A (ja) * 1995-09-19 1999-10-26 イーライ・リリー・アンド・カンパニー 医療用タンパク質をコードしているｄｎａ
AUPN564195A0 (en) * 1995-09-26 1995-10-19 Walter And Eliza Hall Institute Of Medical Research, The A novel haemopoietin receptor and genetic sequences encoding same
JPH10508322A (ja) * 1995-10-12 1998-08-18 スーパーゲン，インコーポレイティド ５βステロイドのリポソーム配合物
WO1997015322A1 (en) * 1995-10-25 1997-05-01 The Regents Of The University Of California Methods for restoring or enhancing reproductive function in reproductively impaired hosts
WO1997016189A1 (en) * 1995-11-01 1997-05-09 Merck & Co., Inc. Combination therapy for the treatment of diabetes and obesity
WO1997016550A1 (en) * 1995-11-02 1997-05-09 Bristol-Myers Squibb Company Polypeptide fragments derived from the obese gene product
US5698389A (en) * 1995-11-16 1997-12-16 Tularik, Inc. Transcriptional promoter of the murine obesity gene
ES2251002T3 (es) * 1995-11-17 2006-04-16 The Johns Hopkins University Inhibicion de sintasa de acido graso, como medio para reducir la masa adipocita.
DK0866720T3 (da) * 1995-11-22 2004-06-14 Amgen Inc OB-protein til forögelse af mager kropsmasse
US6482927B1 (en) * 1995-11-27 2002-11-19 Millennium Pharmaceuticals, Inc. Chimeric proteins comprising the extracellular domain of murine Ob receptor
WO1997020933A2 (en) * 1995-12-06 1997-06-12 Schering Corporation MUTATIONAL VARIANTS OF MAMMALIAN Ob GENE PROTEINS
DE69632546T2 (de) * 1995-12-27 2005-06-30 Genentech, Inc., South San Francisco Ob proteinderivate mit verlängerter halbwertzeit
US5723125A (en) 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
IL125081A (en) * 1996-01-04 2006-08-01 Amgen Inc Ob protein receptor and related compositions and methods
US20020193571A1 (en) * 1996-01-08 2002-12-19 Paul J. Carter Wsx receptor agonist antibodies
US7063958B1 (en) * 1996-01-16 2006-06-20 The Rockefeller University Nucleic acids db, the receptor for leptin
AU1833197A (en) * 1996-01-18 1997-08-11 Progenitor, Inc. Detection of a leptin receptor variant and methods for regulating obesity
AU1747297A (en) * 1996-01-19 1997-08-11 Eli Lilly And Company Obesity protein formulations
EP0784981A3 (de) * 1996-01-19 1999-03-03 Eli Lilly And Company Formulierungen des Obesitätsproteins
JP2000504319A (ja) * 1996-01-19 2000-04-11 イーライ・リリー・アンド・カンパニー 肥満症タンパク質製剤
CA2243505A1 (en) * 1996-01-19 1997-07-24 John Michael Beals Obesity protein formulations
WO1997027286A1 (en) * 1996-01-23 1997-07-31 Progenitor, Inc. Methods for using the obese gene and its gene product to stimulate hematopoietic development
JP2000505791A (ja) * 1996-01-25 2000-05-16 イーライ・リリー・アンド・カンパニー 肥満症タンパク質類似体化合物およびその製剤
AU1838797A (en) * 1996-02-06 1997-08-28 Eli Lilly And Company Obesity protein compounds and formulations thereof
EP0922052A4 (de) * 1996-02-22 2001-08-01 Merck & Co Inc Ratten-spezifische ob-rezeptoren und nukleotide, welche für diese kodieren
IL125933A0 (en) * 1996-03-01 1999-04-11 Amgen Inc Canine ob protein compositions and methods
WO1997035620A1 (en) * 1996-03-26 1997-10-02 Eli Lilly And Company Formulations of ob protein
WO1997038014A1 (en) * 1996-04-04 1997-10-16 Amgen Inc. Fibulin pharmaceutical compositions and related methods
JP2000511406A (ja) * 1996-04-22 2000-09-05 メルク エンド カンパニー インコーポレーテッド レプチンアッセイ
WO1997041217A1 (fr) * 1996-04-30 1997-11-06 Otsuka Pharmaceutical Co., Ltd. GENES RECEPTEURS DE LA PROTEINE ob ET UTILISATION DE CES GENES
JP2000512486A (ja) * 1996-05-06 2000-09-26 メルク エンド カンパニー インコーポレーテッド Ｏｂレセプターイソ型及びそれらをコードする核酸
GB9610195D0 (en) 1996-05-15 1996-07-24 Medical Res Council Assay
PL330361A1 (en) 1996-06-06 1999-05-10 Smithkline Beecham Plc Leptin fragments (ob proteins)
US5919902A (en) * 1996-06-07 1999-07-06 Eli Lilly And Company Leptin bound to inter-alphatrypsin inhibitor and uses thereof
US6001816A (en) 1996-06-20 1999-12-14 Merck & Co., Inc. Gene therapy for leptin deficiency
US9002545B2 (en) 2011-01-07 2015-04-07 Wabtec Holding Corp. Data improvement system and method

Also Published As

Publication number Publication date
US20090318677A1 (en) 2009-12-24
SI0777732T1 (sl) 2012-01-31
EP2402444A1 (de) 2012-01-04
LT4265B (en) 1997-12-29
US7994301B2 (en) 2011-08-09
CN102002102A (zh) 2011-04-06
PT777732E (pt) 2012-01-09
ZA956868B (en) 1996-04-09
US6734160B2 (en) 2004-05-11
DK0777732T3 (da) 2012-01-09
IL188522A0 (en) 2008-04-13
US6703493B1 (en) 2004-03-09
US6001968A (en) 1999-12-14
US20040214214A1 (en) 2004-10-28
LT97020A (en) 1997-09-25
US8173793B2 (en) 2012-05-08
US20110218332A1 (en) 2011-09-08
IL162093A (en) 2008-03-20
US7544492B1 (en) 2009-06-09
US20030040039A1 (en) 2003-02-27
US5935810A (en) 1999-08-10
CO4410343A1 (es) 1997-01-09
US7521258B2 (en) 2009-04-21

Similar Documents

Publication Publication Date Title
ATE526408T1 (de) Modulatoren von dem körpergewicht, entsprechende nukleinsaüre und proteine, und diagnostische und therapeutische anwendungen davon
MX9701200A (es) Moduladores de peso del cuerpo, acidos nucleicos y proteinas correspondientes y sus usos en diagnostico y terapeuticos.
CN113308451A (zh) 工程化的Cas效应蛋白及其使用方法
Biswas et al. Mechanism of DnaB helicase of Escherichia coli: structural domains involved in ATP hydrolysis, DNA binding, and oligomerization
ES2153395T3 (es) Polimerasa termoestable del acido nucleico.
CA2091102A1 (en) Microsomal triglyceride transfer protein
IE911914A1 (en) Novel neurotropic growth factors comprising a homeobox¹peptide
EP4493700A2 (de) Zusammensetzungen und verfahren zur modulation der alpha-synuclein-expression
ATE212060T1 (de) Vom desmingen abstammende amplifizierungssequenzen, vektoren, die diese enthalten und anwendungen derselben zur herstellung von proteinen
JO1694B1 (en) New chemical products
Lars et al. The human lα1 and lα2 germline promoter elements: proximal positive and distal negative elements may regulate the tissue specific expression of Cα1 and Cα2 germline transcripts
Prinz et al. Alternative splicing of mouse IL-15 is due to the use of an internal splice site in exon 5
UA70911C2 (uk) Поліпептид ожиріння (варіанти), відповідні нуклеїнові кислоти (варіанти) та фармацевтична композиція
WO2006066247A2 (en) Methods and compositions for extending telomere length and increasing cell lifespan
Denarier et al. PCR cloning and sequence of the murine GPIIb gene promoter
Lee et al. Selection of a cDNA clone for chicken high-mobility-group 1 (HMG1) protein through its unusually conserved 3′-untranslated region, and improved expression of recombinant HMG1 in Escherichia coli
WO1999004825A8 (en) Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders
Elder et al. Targeting of Sp1 to a non-Sp1 site in the human neurofilament (H) promoter via an intermediary DNA-binding protein
EP1270739B1 (de) Modulierte sekretierte alkalische Phosphatase (SEAP) Reporter Gene und Polypeptide
US20030186905A1 (en) Cis-acting regulatory nucleic acid sequences in the parathyroid hormone3' -untranslated region
Barton et al. Basic concepts in molecular biology
Swartley et al. Co-transcription of a homologue of the formamidopyrimidine-DNA glycosylase (fpg) and lysophosphatidic acid acyltransferase (nlaA) in Neisseria meningitidis
DE60024862D1 (de) "insulinabhängiges sequenz dna bindendes protein-1" (irsdbp-1), dafür kodierendes gen und ihre verwendungen
WO2001034772A3 (en) METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING CHROMOSOME 18q RELATED DISORDERS
US20040018606A1 (en) Control of protein systemic delivery by hypoxia using a tet-HIF1-alpha chimeric transactivator

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0777732

Country of ref document: EP